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Abstract
Topical photodynamic therapy (PDT) is a widely approved therapy for actinic keratoses, Bowen’s disease (squamous cell
carcinoma in situ), superficial and certain thin basal cell carcinomas. Recurrence rates when standard treatment proto-
cols are used are typically equivalent to existing therapies, although inferior to surgery for nodular basal cell carcinoma.
PDT can be used both as lesional and field therapies and has the potential to delay/reduce the development of new
lesions. A protocol using daylight to treat actinic keratoses is widely practised, with conventional PDT using a red light
after typically a 3-h period of occlusion employed for other superficial skin cancer indications as well as for actinic ker-
atoses when daylight therapy is not feasible. PDT is a well-tolerated therapy although discomfort associated with con-
ventional protocol may require pain-reduction measures. PDT using daylight is associated with no or minimal pain and
preferred by patient. There is an emerging literature on enhancing conventional PDT protocols or combined PDT with
another treatment to increase response rates. This guideline, published over two parts, considers all current approved
and emerging indications for the use of topical PDT in dermatology, prepared by the PDT subgroup of the European
Dermatology Forum guidelines committee. It presents consensual expert recommendations reflecting current published
evidence.
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Introduction
This updated guideline seeks to promote safe and effective prac-
tice across Europe in the delivery of topical photodynamic ther-
apy (PDT) in dermatological indications and reflects evidence
derived from a systematic literature review and previous PDT
and disease-specific therapy guidelines.1–6 Recommendations
concerning emerging indications for topical PDT are reviewed
in Part II.7
Photodynamic therapy involves the activation of a photosensi-
tizing drug by visible light to produce reactive oxygen species
within target cells, resulting in their destruction with additional
immune-modulatory effects observed.8 In dermatological
indications, PDT is usually performed by topical application of
precursors of the haeme biosynthetic pathway, in particular 5-ami-
nolaevulinic acid (5-ALA) or its ester, methyl aminolaevulinate
(MAL), converted within target cells into photoactivatable por-
phyrins, especially protoporphyrin IX (PpIX). After an incubation
period, light of an appropriate wavelength activates the photosen-
sitizer promoting the photodynamic reaction. Before light illumi-
nation, it is possible to detect skin surface fluorescence, assisting
detection and delineation of both visible and incipient lesions.
Three agents are currently licensed for use in Europe
(Table 1): MAL (160 mg/g) Metvix/Metvixia (Galderma,
Paris, France) is used along with red light to treat non-hyperker-
atotic actinic keratosis (AK), squamous cell carcinoma in situ
(SCC in situ/Bowen’s disease), superficial and nodular basal cell
carcinomas (sBCC, nBCC), although approvals vary between
countries. A nanoemulsion of 5-ALA (Ameluz; Biofrontera
AG, Leverkusen, Germany) is licensed for PDT in combination
with red light for the treatment of mild and moderate AK, field
cancerization, and superficial and low-risk nodular BCC. A
patch containing 5-ALA (Alacare; Photonamic, Pinneberg,
Germany) is approved for the treatment of mild AK in a single
treatment session in combination with red light without pre-
treatment of the lesion. A 20% formulation of 5-ALA, Levulan
(DUSA Pharmaceuticals, Wilmington, MA, USA), is approved
in N. America and certain other countries for AK, in a protocol
that uses blue light. Many original studies of topical PDT used
non-standardized preparations of ALA made in hospital phar-
macies, so direct comparison of early studies may not be valid.
Treatment is generally well tolerated but discomfort or pain is
common during conventional PDT. Alterations in the way PDT
are delivered, including the use of daylight or shorter photosen-
sitizer application times, are associated with decreased discom-
fort, with licence approvals for daylight PDT for actinic
keratoses using the MAL and nanoemulsion ALA.
Method of action
Photosensitizers
Aminolaevulinic acid is hydrophilic whilst MAL is more lipophi-
lic, and hence, MAL may penetrate more deeply into lesions
although studies that have compared these agents when used to
treat AK, nodular BCC or acne, failed to show a difference in
response with the formulation of ALA used.9–11 More recently, a
nanoemulsion of ALA (Ameluz), which improves ALA stability
and skin penetration, has achieved significantly higher clearance
of patients with AK when compared with MAL.12 A self-adhesive
5-ALA patch (Alacare), directly applied to AK without the need
of lesion preparation, has been shown to be superior to cryother-
apy for mild and moderate thickness AK, providing a clean and
uniform method of photosensitizer application.13
Enhancing photosensitizer penetration may increase the effi-
cacy of PDT, but currently there is no licensed approval for a
protocol that uses a penetration enhancer or iontophoresis. Ele-
vating skin temperature during ALA application may also
improve efficacy as PpIX production is a temperature-dependant
process.14
In nodular BCC of up to 2 mm thickness, a 3-h application of
160 mg/g MAL showed the highest selectivity for tumour, and
this procedure is licensed in the form of two treatments 1 week
apart for BCC.15 It is also licensed as a double treatment for SCC
in situ, but in AK one treatment is recommended, with non-
responders receiving a second treatment at 3 months.
Nanoemulsion ALA is also applied for 3 h when using the con-
ventional PDT protocol, with a repeat treatment at 1 week when
treating BCC, but waiting to 3 months and assessing need for
repeat therapy when treating AK.12
The 20% ALA formulation used with the Blu-UTM system
(blue fluorescent lamps) is licensed for a drug light interval of
18–24 h but is widely used with application times of around 1 h
for AK.16 A shorter incubation time of 1 h with MAL for AK is
also an option given that in a comparison of 1 h vs. 3 h, overall
lesion response rates (after 1 or 2 PDT treatments) were 76% vs.
85%, respectively.17
Additional topically applied photosensitizers including indo-
cyanine green, indole-3-acetic acid,18 hypericin,19,20 silicon
phthalocyanine PDT21 and 3,7-bis (N,N-dibutylamino) phe-
nothiazin-5-ium bromide22 have been assessed in specific indica-
tions but are not licensed, to date.
Light sources and dosimetry
Light sources for conventional PDT A range of light sources
can be used for topical PDT including filtered xenon arc and
metal halide lamps, fluorescent lamps and light-emitting diodes
(LED) and even lasers although coherent light is not required.
Large fields can be treated using narrowband LED devices, e.g.
the Aktilite 128 (Galderma), BF-Rhodo LED (Biofrontera) and
Omnilux PDT (Phototherapeutics, London, UK) each with an
output that matches the 630/635 nm activation peak of PpIX
whilst excluding the extraneous wavelengths present in broad-
band sources, permitting shorter illumination times. Filtered
intense pulsed lights (IPLs) have been successfully used in PDT
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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EDF guidelines on topical PDT – Part 1 2227
for AK, acne and photorejuvenation although they emit different
spectra, resulting in a need to derive specific protocols to achieve
identical radiant exposures.23 Narrow spectrum light sources are
associated with higher response rates, with complete patient
clearance rates of 85% and 68% for nanoemulsion ALA-PDT or
MAL-PDT, respectively, compared with 72% and 61% when
broad spectrum devices were used.12,24
Protoporphyrin IX has its largest absorption peak in the
blue region at 410 nm with smaller absorption peaks at 505,
540, 580 and 630 nm. Most light sources for PDT use the
630 nm absorption peak in the red region, in order to
improve tissue penetration, although a blue fluorescent lamp
(peak emission 417 nm) is recommended in Levulan PDT.
Light dose specifications are included in the product sum-
maries of the topical photosensitizers approved for skin can-
cer indications, whilst dosimetry for emerging inflammatory/
infective dermatoses discussed in Part 2 is not yet standard-
ized. Consideration of high and low dose regimens for PDT
in acne has been reviewed although an optimal protocol has
not been established.7,25
Fractionated illumination Discontinuous illumination (frac-
tionation) may improve the efficacy of PDT by permitting tissue
re-oxygenation during ‘dark’ periods. Studies support superior-
ity of fractionation to conventional illumination in ALA-PDT
for AK (94% vs. 85% at 1 year) and sBCC (88% vs. 75% at
5 years), but not in SCC in situ (88% vs. 80% at 1 year).26–28
Overall clearance of 95% after 2-year follow-up has been
reported in a large series of 552 lesions (AK, SCC in situ, sBCC,
nBCC) following ALA-PDT using two light fractions of 20 and
80 J/cm² at 4 and 6 h separated by a 2-h dark interval.29 An
alternative ALA-PDT fractionation protocol of two doses of
75 J/cm² at 4 and 5 h was associated with an initial 94% clear-
ance rate for nBCC, but with a cumulative failure rate of 30% by
3 years.30 No significant difference in efficacy was observed
when standard red light MAL-PDT was compared with fraction-
ated ALA-PDT in a study of 162 patients with superficial BCC.31
No efficacy improvement has been reported using light fraction-
ation in MAL-PDT, considered to be due to differences in local-
ization between the agents.
Daylight, ambulatory LED and fabric-based laser diode illumi-
nation Daylight is increasingly used as the light source for PDT
in treating AK, with application of either nanoemulsion ALA or
MAL for 0.5 h, followed by exposure to daylight for 2 h, with
no inferiority of efficacy to red light PDT, but with the benefit of
reduced pain.32–34 As well as its potential for AK and field
cancerization, daylight PDT has been assessed for treating
BCC.35
There is also an option for patients to wear a portable LED
device, permitting ambulatory PDT to reduce the need for hos-
pital attendance, with an overall 84% lesion clearance reported
for sBCC and SCC in situ, 1 year following two treatments,
1 week apart, with minimal pain with another research group
demonstrating 90% clearance rate at 12 months in a study of
143 sBCC.36,37
A novel light-emitting, fabric-based laser diode device has
recently been shown to be as effective as conventional PDT in
clearing AK but with minimal pain, with MAL applied under a
transparent occlusive dressing for 30 min then fabric device is
applied and switched on after 30 min, remaining on for
150 min.38
Lesion preparation
Protocols for topical PDT in Europe conventionally recom-
mend some form of lesion preparation to enhance photosen-
sitizing agent absorption and light penetration in MAL-PDT
and nanoemulsion ALA-PDT. Studies using a novel ALA
plaster for mild and moderate thickness AK do not require
prior preparation with results consistent with standard proto-
cols.13,39 Tape-stripping, microdermabrasion or laser ablation,
or gentle curettage can also be used to reduce hyperkeratosis.
Some practitioners have observed reduced efficacy if lesions
are not debrided prior to PDT14,17 whilst others have not
noted increased drug uptake following lesion preparation of
SCC in situ and BCC.40 However, gentle removal of overly-
ing crust and scale is commonly performed for moderate
thickness/hyperkeratotic AK and for SCC in situ and superfi-
cial BCC. Lesion preparation is probably more important
when treating nodular BCC by PDT with recommended
practice to gently remove overlying crust with a curette/scal-
pel in a manner insufficient to cause pain, and thus not
requiring local anaesthesia. Some practitioners perform a
more formal lesion debulking days/weeks prior to PDT, with
92% of BCC clearing following a single session of ALA-PDT
in one study.41 The effect of pre-PDT deep curettage in
another study of thick (≥2 mm) BCC reduced mean tumour
thickness from 2.3 mm (range 2.0–4.0) by 50%, with 3-
month tumour response of 93%.42 In a comparison study of
PDT (ALA and MAL) with or without debulking immedi-
ately pre-photosensitizer application, residual nBCC was more
often observed in lesions that were not debulked.10 Under
standardized conditions in a randomized clinical trial, PpIX
accumulation was most enhanced after ablative fractional
laser pretreatment, followed by microdermabrasion, micro-
needling and curettage.43
Practitioners typically cover treatment sites with light occlu-
sive dressings, on the presumption that full exposure to ambient
light during the incubation period will lead to increased activa-
tion of PpIX superficially reducing the opportunity for deeper
photosensitizer penetration before photoactivation. PDT with
occlusion is routine in conventional MAL and nanoemulsion
ALA-PDT, but is not performed when using Levulan PDT and
no occlusion is required for daylight PDT.32–35
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Treatment protocols
Conventional topical PDT
Recommended protocols for ALA-PDT and MAL-PDT using
currently licensed photosensitizing agents for NMSC indications
are summarized in Table 1. Conventional PDT involves applica-
tion of a topically applied photosensitizing agent, occluded for
3–4 h depending on product, then illuminated typically by a
narrowband red LED light source. Protocols employed in emerg-
ing indications are discussed with each indication.
Daylight PDT (DL MAL-PDT, DL ALA-PDT)
Daylight PDT is performed with initial widespread application of
an organic sunscreen followed approximately 15 min later by
lesion preparation, then nanoemulsion ALA or MAL to treatment
area, without occlusion (details Table 1).44 Within 30 min of
application, patients are exposed to daylight for 2.0 h with licensed
approvals for AK and field cancerization.45 Alternative methods of
delivering light equivalent to daylight, but avoiding the limitations
of climate considerations, are emerging, including simple use of a
glasshouse and attempting to simulate daylight indoors.46 The
potential to deliver daylight MAL-PDT at home has demonstrated
high levels of patient satisfaction, effectiveness and tolerability.47
Ambulatory, textile, pulse and temperature-modulated
PDT
The protocol for ambulatory PDT, using an inorganic LED
device, involves lesion preparation (maximum size 1.8 mm) and
cream application before the light-emitting ‘plaster’ is applied.
The device automatically switches on after the incubation per-
iod, to deliver a total dose of 75 J/cm at 7 mW/cm, then off at
end of procedure permitting treatment outwith the clinic.36,37
Studies are ongoing to refine ‘Textile PDT’ where red 635 nm
light is delivered through fabric from laser diodes, to slowly expose
the skin to the same light dose as for conventional PDT.38 As light
intensity is reduced and incubation short, treatment is almost
pain-free. The fabric allows for uniform light distribution even on
curved surfaces, with potential to treat much larger areas.
In a novel protocol ‘pulse-PDT’, MAL is applied for 30 min
with red light illumination after 3 h, with equivalent efficacy to
conventional MAL-PDT in treating AK when compared in a
randomized clinical trial.48 Treatment-induced erythema was
reduced, with further reduction if a superpotent topical corticos-
teroid is applied just before and after PDT. Another centre has
proposed ‘temperature-modulated PDT’ where sustained clear-
ance of 90% of 724 AK at 1 year was achieved by warming the
skin during 1 h of Levulan ALA incubation.49
Fluorescence diagnosis
The detection of skin surface fluorescence, visible following
application of ALA and MAL, can be utilized as a non-invasive
method to assist in lesion definition as well as in identifying per-
sistent/recurrent disease that may not be clinically obvious.50
Compared with relatively subjective assessment of fluorescence
using the Wood’s lamp, a CCD camera system can provide
semi-quantitative measurements of PpIX within dermatological
lesions. The value of PpIX imaging to outline tumours has
shown contradictory results in a review of published studies.51
Even when utilized to reduce stages in Mohs surgery, the tech-
nique did not permit time saving overall.52
Measurement of fluorescence during MAL-PDT has shown
extent of photobleaching, but not total initial PpIX fluorescence,
as predictive of lesion clearance.53 In another study, fluorescence
diagnosis in keratinocyte intraepidermal neoplasias was unable
to discriminate between lesions or proliferative activity, although
hyperkeratosis was an important determinant of macroscopic
fluorescence intensity.54 Intensity of pain has been associated
with fluorescence intensity and can help anticipate patients more
likely to require active pain management.55 In practice, in addi-
tion to helping predict likelihood of pain, PDT practitioners find
observing strong fluorescence is helpful in supporting clinical
suspicion of recurrence whilst absence can also be supportive of
clinical indication of clearance of disease after treatment.
Current indications
Actinic keratosis (strength of recommendation A, quality of
evidence 1) (approved indication)
Conventional PDT for AK Conventional PDT with 5-ALA,
nanoemulsion 5-ALA and MAL has been widely studied for thin
and moderate thickness non-hyperkeratotic AKs of the face and
scalp with typical lesion clearance rates of 81–92% 3 months
after treatment.12,13,24,56–58 Conventional nanoemulsion ALA-
PDT was superior to MAL in clearing thin and moderate thick-
ness AK from face/scalp, with clearance of 90% vs. 83% of
lesions (respective complete clearance rates of 78% vs. 64%)
12 weeks after one or two PDT treatments.12 Similar lesion
recurrence rates were observed following nanoemulsion ALA-
PDT and MAL-PDT of 22% and 25%, respectively, at
12 months, with subset analysis showing improved response
with lesions treated using the narrow wavelength LED lamps.59A
randomized intra-individual study of 50 patients compared
nanoemulsion ALA with MAL, demonstrating similar lesion
clearance rate after a single treatment (ALA: 90%, MAL: 88%)
but with more intense skin reactions observed with ALA, pre-
sumed due to less selectivity, although this was associated with
higher accumulation of PpIX.60 One year of lesion clearance
rates of 78% and 63–79% have been reported following Levulan
ALA-PDT (up to two treatments) and patch ALA-PDT (single
treatment), respectively.39,61 A randomized multicentre study of
conventional nanoemulsion ALA-PDT achieved a patient
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clearance rate of 91% (vs. 22% placebo) with additional benefits
to skin quality in field-directed treatment of AK.62
Comparison of conventional PDT with other therapies for
AK Compared with cryotherapy, MAL-PDT achieved an ini-
tially superior cure rate than cryotherapy (87% vs. 76%), but
with equivalent outcome after retreatment of non-responders
(89% vs. 86%) in a randomized intra-individual study of 1501
face/scalp AK.58 ALA-PDT using the self-adhesive patch cleared
82–89% of mild or moderate AK in patients with 3–8 face/scalp
lesions, superior to the 77% clearance rate in a comparator
group receiving cryotherapy.13 MAL-PDT is more effective than
diclofenac and hyaluronic acid cream as well as to trichloroacetic
acid, with non-formulary ALA-PDT more effective than CO2
laser ablation, in separate comparison studies.63–65
Two systematic reviews looked at the use of conventional
PDT against other therapies. A Cochrane Library systematic
review searched databases up to March 2011, identifying 83
RCTs covering 18 AK therapies, including PDT.66 Whilst the
primary outcome ‘participant complete clearance’ significantly
favoured four field-directed topical treatments compared to
vehicle or placebo, it favoured the treatment of individual AK
lesions with PDT compared to placebo-PDT with ALA using
blue light, ALA using red light, and MAL with red light. ALA-
PDT was also significantly favoured compared to cryotherapy.
Based on investigator and participant evaluation, imiquimod
and PDT resulted in better cosmetic outcomes than cryother-
apy and 5-fluorouracil. A further systematic review performed
in 2013 undertook to compare the evidence of the effectiveness
of PDT compared with other therapies, restricted to RCTs
with at least 10 participants.67 Thirteen studies were included
in the final synthesis, of which 4 were eligible for final meta-
analysis. The only comparator for which meta-analysis was
performed was cryotherapy. PDT was concluded to offer a
14% better chance of complete lesion clearance at 3 months
after treatment than cryotherapy for thin AKs on the face and
scalp.
Combination of conventional PDT with other therapy for
AK There is emerging use of combination therapies in AK,
either combining lesional with field therapy or two field thera-
pies. A recent meta-analysis investigated whether conventional
PDT combined with other field therapies is superior to PDT
alone.68 From 1800 references, 10 RCTs with a total sample of
n = 277 were included. Four studies explored the combination
of PDT with imiquimod, three with 5-fluorouracil and one each
with ingenol mebutate (IM) gel, tazarotene gel and calcipotriol
ointment, respectively. Overall, patients treated with a combina-
tion showed significantly higher clearance rates compared with
monotherapy. Considering the specific therapies, in a subset
analysis, topical imiquimod combined with PDT, either prior to
or following PDT, showed higher participant complete clearance
rates than monotherapy. Pretreatment with topical 5-fluoroura-
cil cream, applied twice daily for 6–7 days prior to PDT (both
ALA and MAL), led to a mean improvement in lesion clearance
of 11–30% compared with PDT alone. Pretreatment of acral AK
lesions with 0.1% tazarotene gel may also enhance the effect of
PDT but this study only had 10 participants.69 Combination
ALA-PDT with ingenol did not achieve a significant differential
response rate, but the response rate of 92% reduction in AK with
ingenol alone is unusually high compared with routine prac-
tice.70
A randomized split-scalp study compared calcipotriol once
day for 15 days prior to conventional MAL-PDT vs. conven-
tional PDT. Clinical and histological improvement was superior
on the calcipotriol-assisted side (overall AK clearance rates were
92.1% and 82.0%, respectively) with greatest improvement for
grade II AKs (90% vs.63%) although pain and also local side-
effects were greater with the combined protocol.71 A prospective
randomized clinical trial using ablative fractional laser-assisted
MAL-PDT after twice daily topical 0.005% calcipotriol pretreat-
ment for 2 weeks showed a higher rate of complete response of
facial AK with the combined treatment (89% vs.80%) and lower
recurrence rate at 12 months (5% vs.10%).72
A systematic review and metaanalysis of laser-assisted PDT
for AK identified seven randomized controlled trials with four
included in the analysis.73 Laser-assisted PDT showed signifi-
cantly higher clearance rates than PDT monotherapy with no
difference in pain intensity between laser-assisted PDT and PDT
or laser monotherapy. Such an approach potentially complicates
the ease of delivery of PDT and increases healthcare costs and
may be best utilized for difficult to treat acral and/or hyperkera-
totic AK and AK in the immunosuppressed.
Daylight PDT for AK DL MAL-PDT is as effective, but less
painful, than conventional PDT with a randomized intra-indi-
vidual trial of patients with multiple AK on face/scalp demon-
strating a reduction, after a single treatment, of 79% on the
daylight side compared with 71% when standard LED illumi-
nation was used.74 Subsequent multicentre studies have
demonstrated that daylight exposure of 1.5 h is as effective as
2.5 h, but that lesion response is highest for thin lesions
(76%) compared with clearance rates of 61% and 49% for
moderate and thick AK, respectively.75,76 Reduced efficacy of
thicker lesions was demonstrated in a trial with 3 months of
clearance rates for types I, II, and III AK of 76%, 61% and
49%, respectively, after a single treatment of DL-PDT, with
considerable variation in response between centres.76 A study
assessing the impact of latitude on its delivery identified that
DL MAL-PDT can be performed throughout the summer and
until mid-September in Reykjavik and Oslo, late October in
Copenhagen and Regensburg, mid-November in Turin, and all
year in Israel.77 During these months, it should be possible to
achieve active PpIX-weighted daylight dose as above 8 J/cm2,
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and a maximum daytime temperature of 10°C, to permit
effective treatment.
Two pivotal intra-individual multicentre comparative studies
in Australia and Europe both observed that DL MAL-PDT was
non-inferior to conventional PDT with the Australian study
reporting lesion clearance rates of the mild AK treated of 89%
and 93%, respectively, 12 weeks after one treatment session.32,33
The European study observed equivalent responses of 70% and
74%, both values lower as this study included patients with mild
and moderate thickness lesions. Daylight PDT was virtually pain
free in comparison with conventional PDT and was as effective
whether performed in sun or cloudy conditions. Both high effi-
cacy and patient satisfaction were demonstrated in a further
multicentre study conducted over six European countries, in 325
patients receiving a single treatment of DL MAL-PDT for face
and/or scalp AK, demonstrated efficacy at 3 months was at least
much improved in 83.5% of patients, with 45.9% of patients
requiring no retreatment.78
DL ALA-PDT using nanoemulsion ALA has at least as effec-
tive as DL MAL-PDT in treating mild and moderate AK. In a
randomized split-face trial, 13 patients with 177 grade I-III AK,
DL ALA-PDT cleared 85% of AK compared with 74% treated by
MAL.34 The per-patient half-face analysis showed ALA to have a
significantly higher clearance rate for grade I AKs than did MAL,
but for thicker grades, clearance was equal. A recent multicentre
intra-individual comparison trial has compared DL ALA-PDT
with DL MAL-PDT in 52 patients with 3–9 mild to moderate
thickness AK on the face/scalp.79 Equivalent efficacy was demon-
strated at 3 months, with lesion clearance rates of 79.8% with
ALA and 76.5% with MAL, although recurrences at 1 year were
higher with MAL (31.6% vs. 19.9%). In an non-sponsored ran-
domized comparison trial, DL ALA-PDT was more effective
than DL MAL-PDT in the per-patient half-face analysis of clear-
ance (79.7% vs. 73.5%).80 In an evaluation of patient self-appli-
cation of DL MAL-PDT, there was high patient satisfaction and
at 3 months, with 62% of treated AK were clear.47
Comparison of DL-PDT with other therapies There is limited
direct comparison evidence of DL-PDT with standard therapies.
DL-PDT has been compared with IM in the treatment of 27
patients with 323 grade I and II AK with identical response
rate.81
Combination therapy using DL-PDT A case series of 11 subjects
with grade I-III AKs evaluated with a split-face design the effect
of once-daily calcipotriol ointment for 15 days prior to DL
MAL-PDT compared with PDT alone. After 3 months, the com-
plete response rate was 85% and 70% although the combination
was associated with more erythema and desquamation.82 A ran-
domized controlled trial compared DL MAL-PDT followed by
diclofenac/hyaluronic acid gel 30 days before or after, compared
with PDT alone; after 12 months, no significant difference in
resolution of the AK was observed (91.2% vs.90%).83 Pretreat-
ment with ablative fractional laser, compared with microder-
mabrasion, was more effective (81% vs.60% AK clearance) in
patients with extensive field cancerization using DL MAL-PDT
in a recent randomized trial.84
PDT for acral AK Photodynamic therapy is less effective for AK
on acral sites, probably in part due to a higher proportion of
thicker lesions on these sites. A study comparing conventional
MAL-PDT with cryotherapy for AK on the extremities demon-
strated inferior efficacy with PDT, with clearance of 78% of
lesions at 6 months compared with 88% for cryotherapy.85
However, in a right/left comparison study with imiquimod, con-
ventional ALA-PDT cleared significantly more moderate thick-
ness AK lesions (58% vs. 37%), and equivalent numbers of thin
AK on the hands/forearms (72% lesions).86 A further random-
ized placebo-controlled study of MAL-PDT using an IPL to treat
AK on the dorsal hands achieved complete remission of 55%
compared with 3% with light alone.87 Similar to conventional
PDT, 7 days pretreatment with 5-fluorouracil cream has
enhanced DL MAL-PDT in a study treating AK on dorsum of
hands, with superior clearance rates after single PDT session of
62.7% vs. 51.8% compared with PDT alone.88
PDT for actinic cheilitis A series of 40 patients saw complete
clinical response at 3 months in 26 patients with actinic cheilitis
following conventional ALA-PDT although with histological evi-
dence of recurrence in nine patients over 18 months of follow-
up.89 Conventional MAL-PDT clinically cleared 47% of 15
patients although histological clearance was evident in only 4.90
In a retrospective analysis of real-life practice, PDT cleared 27 of
43 (63%) patients with complete response maintained at
4.2  5.9 months.91 A recent systematic review of PDT in acti-
nic cheilitis reviewed 15 eligible studies with a complete response
of 62% at final follow-up ranging from 3 to 30 months,
although histological cure, where assessed, was lower, at 47%
overall at final follow-up (1.5–30 months).92
To achieve improved response rate, cotton rolls and lip
retractors can be used, as well as considering repeat treatments
and/or combining with other therapies. Sequential MAL-PDT
then imiquimod cream achieved clinical clearance in 80% (his-
tological 73%) in a study of 30 patients.93 Ablative factional
laser pretreatment also has significantly improved response to
use of PDT in actinic cheilitis, clearing 92% lesions at
3 months (compared with 59% by MAL-PDT alone), with an
8% recurrent rate (compared with 50% with MAL-PDT alone)
at 12 months.94
Two recent publications detail DL MAL-PDT for actinic
cheilitis which achieved sustained response in 5/10 patients over
6–12 months of follow-up in a study of two treatments 7–
14 days apart, whilst a 91% cure rate in 10/11 patients was
achieved using repeated treatments – mean 2.8.95,96
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Therapy guidelines identify PDT as effective both as a lesion
and field-directed treatment and suggest PDT has a role where
AKs are multiple/clustered, as a suitable choice for patients wish-
ing to manage background actinic changes, and as part of main-
tenance treatment for low-grade AKs in sun damaged skin.97,98
PDT remains a predominantly hospital-based therapy in most
countries whilst many patients with AK are treated by primary
care physicians. However, high quality of cosmesis consistently
observed in PDT studies for NMSC indications including AK,
combined with increasing emphasis on patient choice over ther-
apy, may see increased demand for topical PDT. A recent sys-
tematic review of AK clinical guidelines to construct a treatment
algorithm positioned DL-PDT a valuable option for patients
with multiple AKs in small or large fields.99
Squamous cell carcinoma in situ (Bowen’s
disease)/invasive SCC
Squamous cell carcinoma in situ (strength of
recommendation A, quality of evidence 1) (approved
indication)
Lesion clearance rates of 88–100% are reported for SCC in situ
3 months after one or two cycles of conventional MAL-PDT,
with 68–89% of treated lesions remaining clear over follow-up
periods of 17–50 months.100–104 Conventional MAL-PDT is
approved in many countries for Bowen’s disease, but no formu-
lation of ALA-PDT is licensed.
In a Cochrane review of treatments for Bowen’s disease, PDT
appeared to be an effective treatment and offer the benefit of
minimal scarring compared with cryotherapy or 5-fluoroura-
cil.105 There are limited data to demonstrate superiority of PDT
to standard therapy, with conventional MAL-PDT compared
with cryotherapy or topical 5-fluorouracil in a large European
study with 3 month lesion response rates similar with all regi-
mens (93% for MAL-PDT, 86% for cryotherapy, 83% for
5-fluorouracil).100 Although PDT had a superior 1-year lesion
clearance rates; all three therapies were similar after 2 years with
68% clear following PDT, 60% after cryotherapy and 59% after
5-fluorouracil.101 A similar 3-month efficacy rate of 88% was
observed in an open study of MAL-PDT for 41 SCC in situ with
sustained clearance at 24 months of 71%.102 Further open stud-
ies assessing durability of response to MAL-PDT observed 76%
and 89% sustained clearance after follow-up periods of 17 and
50 months, respectively.103,104 Non-formulary ALA-PDT has
been compared with cryotherapy and with 5-fluorouracil in
small studies where PDT proved superior in efficacy and adverse
events in comparison with 5-fluorouracil, as well as being less
painful compared with cryotherapy.106,107
Lesion size impacts on clearance rate with 82% of lesions up
to 14 mm clear at 12 months reducing with increasing size to
only 55% of lesions 30 mm or larger.100 Larger plaques over
3 cm responded to a cycle of MAL-PDT, two treatments 7 days
apart, clearing 90% of 23 lesions and observing recurrence in
only 3 up to 12 months reducing clearance to 83%, with another
study of identical design initially clearing 90% of 37 lesions, not-
ing four recurrences after 12 months reducing clearance rate to
78%.108,109
Emerging literature on combination PDT in comparison with
PDT alone observes that ablative fractional laser-assisted MAL-
PDT was significantly more effective than PDT alone in two
studies, clearing 94% of plaques compared with 73% at 1 year in
one study, whilst in a 5 year follow-up study, ablative laser-
assisted MAL-PDT achieved sustained clearance rates of 85% vs.
45% with PDT alone.110,111 A similar superiority of response has
been observed in a small comparison trial of microinvasive SCC
where ablative fractional laser-primed MAL-PDT achieved
3 months of clearance rates of 84% vs. 52% with PDT alone,
with reduced recurrence rates (12% compared with 64% at
2 years for PDT alone).112 ALA-PDT combined with CO2 laser
achieved clearance at 6 months of 64% of lesions compared with
18% with laser alone in a trial of 22 lesions.113
The therapeutic effect of PDT may be enhanced by sequential
use along with topical imiquimod, although clinical experience,
to date, is limited.114,115
Severe atypia and higher age were associated with increased
risk of treatment failure following PDT in a retrospective study
re-examining histology and clinical features of patients treated
with PDT over 5 years.116 Failure to correctly perform PDT may
also impact efficacy with a national prospective observational
study of MAL-PDT in France noting incorrect delivery of treat-
ment in 23% of patients.117
A comprehensive disease-specific guideline pointed to the value
of PDT for all lesions in poor healing sites and for large lesions in
good healing sites, supported by a recent review.118,119 PDT is
considered a fair choice for small lesions in good healing sites,
multiple lesions, facial, digital, nail bed and penile lesions, in com-
parison with other therapeutic options. In a patient-reported out-
come study, satisfaction with ALA-PDT for SCC in situ was high,
with 90% of respondents indicating a very favourable impression
of the treatment, although with burning sensation described in
21%.120 A national audit of use of PDT in clinical practice in Scot-
land confirmed that 27% of all use was for patients with Bowen’s,
just behind use for sBCC (33%) and AK (35%).121
Invasive squamous cell carcinoma SCC (strength of
recommendation D, quality of evidence 11-iii)
There remain limited data on the efficacy of topical PDT for pri-
mary cutaneous invasive SCC although MAL-PDT can achieve
higher response rates in microinvasive disease – 3-month clear-
ance rates of 80%, with 58% still clear at 24 months.102
Although 45% of nodular invasive SCC did appear to initially
clear, clearance rate dropped to 26% by 24 months. The degree
of cellular atypia is a negative prognostic factor, suggesting
poorly differentiated keratinocytes are less sensitive to PDT. A
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subsequent retrospective real-life audit of PDT identified an
additional 17 invasive SCC (with initial clearance in 58.8%) with
two recurrences reducing sustained clearance to 47%.91 There is
concern that not only does SCC not respond adequately to PDT,
but that tumour could become more histologically aggressive
and resistant to PDT. A study observed genomic imbalances
related to CCND1, EFGRs and particularly MAP3K1 genes
appear to be involved in development of resistance of SCC to
PDT.122 MAL-PDT was successfully used to treat verrucous car-
cinoma where surgery was contraindicated, indicating a case-
specific role.123 However, in view of its metastatic potential and
reduced efficacy, PDT is not recommended for invasive SCC.
Basal cell carcinoma
Basal cell carcinoma: superficial basal cell carcinoma
(strength of recommendation A, quality of evidence 1)
(approved indication) nodular basal cell carcinoma
(strength of recommendation A, quality of evidence 1)
(approved indication) efficacy of PDT for sBCC and nBCC
Initial clearance rates after conventional MAL-PDT of 92–97%
for primary sBCC are reported, with recurrence rates of 9% at
1 year although 22% of initially responding lesions recurred
over 5 years of follow-up.124,125 91% of primary nBCC were
clear at 3 months following MAL-PDT, with a sustained clear-
ance of 76% after 5 years.15,126
Histologically confirmed response rates were observed in a
further two randomized studies of MAL-PDT for nBCC, with
overall clearance in 73%, most effective for facial lesions where
89% achieved complete histological response.127A poorer
response was reported in a large series of 194 BCC, with an 82%
clearance rate for sBCC, but only 33% of nodular lesions clear-
ing following MAL-PDT although the authors describe no
debulking of the tumour prior to PDT.128
Ambulatory PDT has also been used to treat small sBCC with
overall response rate for lesions on 84% at 1 year in one study
and 90% in a more recent study.36,37 There is limited experience
of DL MAL-PDT for sBCC, which cleared 90% of 30 lesions at
3 months, although six recurrences occurred during 12 months
of follow-up.35 Sequential topical imiquimod 5% cream followed
by DL MAL-PDT vs. PDT alone in sBCC achieved improved
response rate if patient had two or more BCC, although no differ-
ence was observed for patients with single lesions.129
Nanoemulsion ALA-PDT was compared with MAL in the
treatment of non-aggressive BCC in a randomized, phase III trial
with 281 patients randomized. Of the ALA-treated patients,
93.4% were complete responders compared with 91.8% in the
MAL group, establishing non-inferiority, with recurrence rate
<10% by 1 year.130
In a randomized comparison trial of single vs. fractionated
ALA-PDT for sBCC, 5 years after treatment, fractionated PDT
produced a superior response (88% vs. 75%, respectively).27
Fractionated ALA-PDT was equivalent to surgery in initially
clearing lesions but with a 31% failure rate over a median of
5 years after PDT, compared with only 2% postsurgery when a
75J/75J protocol was used although 80% of lesions remained
clear at 2 years using a 20J/80J fractionated dosing.30,131 Success
of treatment depended on tumour thickness, with probability of
recurrence-free survival over 5 years 94% if tumour ≤0.7 mm,
compared with 65% for thicker lesions.
A study sought to evaluate whether fractionated ALA-PDT is
superior to conventional MAL-PDT for sBCC. After 12 months,
six treatment failures followed ALA-PDT with 13 after MAL-
PDT. The 12-month cumulative probability of remaining free
from treatment failure was 92.3% for ALA-PDT and 83.4% for
MAL-PDT, failing to reach significance.31 In a comparison of
ALA-PDT vs. simple excision surgery for sBCC and nBCC,
response rates were similar at 95.83% after PDT vs. 95.65% after
surgery, with similar 25-month follow-up recurrence rates of
4.16% vs. 4.34%.132
Comparison with other therapies Methyl aminolaevulinate-
PDT was equivalent to surgery (92% vs. 99% initial clearance,
9% and 0% recurrences at 1 year) for sBCC but inferior to exci-
sion for nBCC when recurrence rates are compared (91% vs.
98% initial clearance, 14% and 4% recurrences at 5 years).125,126
Cosmetic outcome is superior following PDT. Clearance rates
were equivalent when MAL-PDT was compared with cryother-
apy for sBCC, 97% and 95% at 3 months, respectively, with
overall clearance after 5 years identical at 76% of lesions initially
treated, but with superior cosmesis following PDT.124 In a ran-
domized pilot study of PDT with minimal curettage pre-ALA
application vs. conventional surgery, there was also no evidence
of superiority of PDT to surgery.133A single-blind randomized
non-inferiority comparison of MAL-PDT (two treatments
1 week apart) with imiquimod cream or topical 5-fluorouracil
for sBCC achieved tumour-free rates at 12 months of 73%, 83%,
and 80%, respectively, falling to 58%, 80% and 68% at
36 months, indicating that using these protocols, 5-fluorouracil
was non-inferior and imiquimod superior to one cycle of MAL-
PDT.134
Prediction of PDT response in BCC Responsiveness of BCC is
influenced by lesion thickness, with reduced efficacy with
increasing tumour thickness in a study using ALA-PDT.135
Lesions in the H-zone also have reduced sustained clearance
rates.136 A 10-year clinical and histological follow-up of 60 BCCs
treated by ALA-PDT, originally <3.5 mm thick, reported 75% of
treated sites remained disease free at 120 months.137
There has been debate whether treatment failures of BCC
could be due to PDT modifying histological subtype. However, a
recent study reported aggressive treatment failure recurrences
after non-invasive therapy for superficial BCC occur most often
within the first 3 months post-treatment, probably indicating
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under diagnosis of more aggressive components in the primary
tumour rather than transformation.138
Combination therapy with PDT for BCC Results, to date, are
mixed regarding the advantage of pretreatment with laser before
PDT for BCC. Combined therapy using an UltraPulse CO2 laser
and MAL-PDT with repeat PDT 1 week later achieved a recur-
rence-free clearance rate of 97% after a mean follow-up of
32 months, in 177 BCC of different subtypes, similar to the
100% clearance rate at 18 months for 13 nodular BCC treated
with this combination.139,140 Fractional laser as pretreatment
before ALA-PDT for nBCC increased response rate from 80% to
93%.141 In a randomized trial, facial nodular BCC received Er:
YAG AFL-PDT (one session) or conventional MAL-PDT (two
sessions), with clearance at 3 months of 76% with AFL-PDT and
43% with MAL-PDT.142 However, in a further comparison of
combined laser with PDT, response rate was only slightly
increased to 99% compared with 95% for MAL-PDT alone in a
study of nBCC using a Er:YAG laser.143 Long-term efficacy was
similar after MAL-PDT and fractional laser-mediated PDT for
high-risk facial BCC with clearance at 12 months of 63% com-
pared to 56% for PDT alone.144
A pilot study of 34 patients supplemented Levulan ALA-PDT
with topical imiquimod cream (twice weekly for 5 weeks after
PDT) for recurrent BCC observed higher clearance rate of 75%
with the combination compared with 60% by PDT alone.145
Combining imiquimod with MAL-PDT for BCC may achieve
improved response, but requires further study beyond current
case series.146–148
Patients with naevoid basal cell carcinoma syndrome (NBCCS)
can benefit from PDT with several series and cases reported. A
large cohort of 33 patients were treated by topical or systemic
PDT depending on whether lesions were less than/greater than
2 mm in thickness when assessed by ultrasound, with an overall
local control rate at 12 months of 56.3%.149 A short report
observed that MAL-PDT for NBCCS improves patient satisfac-
tion and reduces the need for surgical procedures.150
Conventional MAL-PDT or nanoemulsion ALA-PDT should
be considered in patients with non-aggressive, low-risk BCC, i.e.
superficial and nodular types, not exceeding 2-mm tumour
thickness, where surgery is not suitable or contraindicated due
to patient-related limitations (comorbidities, medications, logis-
tic difficulties).6 Less common histologic variants, morphoeic,
pigmented and micronodular types, as well as areas with higher
risk of tumour survival and deep penetration (facial ‘H’-zone),
should not be treated with PDT. A systematic review and met-
analysis concluded that PDT is effective for low-risk BCC, with
excellent cosmesis and safety. Imiquimod has higher efficacy
than single-cycle PDT but more adverse effects, with surgery
offering the highest efficacy.151 This is in accordance with a fur-
ther review and metanalysis of sBCC treatment options, where
pooled estimates from randomized and nonrandomized studies
showed similar tumour-free survival at 1 year for imiquimod
and PDT, with highest success in studies with repeated treat-
ments.152 PDT is recommended as a good therapy for primary
sBCC, fair for primary low-risk nBCC and the treatment of
choice for large low-risk primary sBCC.153
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